Starpharma announces a research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy asset

CAR-T Digest - August 2020

30 September 2025: Starpharma announces a research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy asset

Starpharma signed a research and option agreement with Radiopharm Theranostics after six months of preliminary research under its Star Navigator program
The collaboration will use Starpharma’s proprietary DEP platform to develop and manufacture a dendrimer-drug conjugate incorporating Radiopharm’s radiopharmaceutical molecule
Radiopharm gains an exclusive option to license the asset, with a AUD $0.5M option fee, and if exercised, Starpharma could receive a AUD $2M upfront payment, up to AUD $89M in milestones, plus royalties
This marks Starpharma’s first radiopharmaceutical partnership and the first Star Navigator program to progress into a formal collaboration